Related Experiment Video
Updated: Mar 30, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Proteomic Study to Survey the CIGB-552 Antitumor Effect
Arielis Rodríguez-Ulloa1, Jeovanis Gil1, Yassel Ramos1
1Department of Proteomics, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba.
Abstract:
CIGB-552 is a cell-penetrating peptide that exerts in vitro and in vivo antitumor effect on cancer cells. In the present work, the mechanism involved in such anticancer activity was studied using chemical proteomics and expression-based proteomics in culture cancer cell lines. CIGB-552 interacts with at least 55 proteins, as determined by chemical proteomics. A temporal differential proteomics based on iTRAQ quantification method was performed to identify CIGB-552 modulated proteins. The proteomic profile includes 72 differentially expressed proteins in response to CIGB-552 treatment. Proteins related to cell proliferation and apoptosis were identified by both approaches. In line with previous findings, proteomic data revealed that CIGB-552 triggers the inhibition of NF-κB signaling pathway. Furthermore, proteins related to cell invasion were differentially modulated by CIGB-552 treatment suggesting new potentialities of CIGB-552 as anticancer agent. Overall, the current study contributes to a better understanding of the antitumor action mechanism of CIGB-552.
Insights
CIGB-552, a cell-penetrating peptide, shows anticancer effects by interacting with proteins involved in cell proliferation and apoptosis. This study reveals its mechanism, including NF-κB pathway inhibition and modulation of cell invasion proteins.
Area of Science:
- Proteomics
- Cancer Biology
- Molecular Pharmacology
Background:
- CIGB-552 is a cell-penetrating peptide with demonstrated in vitro and in vivo antitumor activity.
- Understanding the molecular mechanisms underlying its anticancer effects is crucial for therapeutic development.
Purpose of the Study:
- To elucidate the molecular mechanisms of CIGB-552's antitumor activity.
- To identify proteins and signaling pathways modulated by CIGB-552 in cancer cells.
Main Methods:
- Chemical proteomics was employed to identify CIGB-552 interacting proteins.
- Temporal differential proteomics using iTRAQ quantification identified CIGB-552 modulated proteins.
- Analysis was conducted in cultured cancer cell lines.
Main Results:
- CIGB-552 was found to interact with at least 55 proteins.
- Proteomic analysis identified 72 differentially expressed proteins in response to CIGB-552.
- Key pathways identified include cell proliferation, apoptosis, and NF-κB signaling inhibition.
- Proteins associated with cell invasion were also modulated, suggesting new therapeutic potential.
Conclusions:
- Proteomic approaches provide insights into CIGB-552's antitumor mechanism.
- CIGB-552 modulates critical cellular processes, including proliferation, apoptosis, and invasion.
- The findings support CIGB-552's potential as an anticancer agent and warrant further investigation.
